Dr G Ranga Raman

MBBS, MD, DM(Medical oncologists), ICMLF
Sr. Consultant Medical oncologists
Experience: 10 Years
Location: Nellore
Timings : 10 AM - 4 PM

SGPGI : Hematology; PDT(2010 - 2010)
NRSMCH: Hematology; PDT (2011 - 2011)
BIACRI: Medical Oncology ; Jr. Consultant (2012-2012)
NIMS Medical Oncology ; DM Resident (2013-2015)
HCG Curie Cancer Centre: Medical Oncology ; Head of Department (2015-2021)
Medicover Cancer Institute: Medical Oncology; Senoir Consultant (2021- to present)

Outcomes in pediatric CML in a developing country – Beyond the disease biology”. journal of Clinical oncology 32,2014, no.15_suppl e21005 .
Prognostic significance of NLR kinetics in operable triple negative breast cancer. e14201 journal of Clinical oncology 37,2019, no.15_suppl.
Cytogenetic and molecular response rates in AYA CML CP patients on imatinib based on the baseline BMI”, Annals of Oncology, Volume 27, Issue suppl_9, December 2016, mdw586.009,
Is rituximab-based chemotherapy a standard practice in the treatment of B-NHLs in the developing world. journal of Clinical oncology 31,2013_suppl e19533
Secondary malignancies in CML patients: a retrospective analysis from tertiary care center in India” Annals of Oncology, Volume 26, Issue suppl_9, 1 December 2015, Page ix92,

Timings: Mon-Sat: 10am-4pm